AI And Blood Diagnostics Will Transform Early Cancer Detection

Published
20 Mar 25
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$61.33
4.5% undervalued intrinsic discount
14 Aug
US$58.57
Loading
1Y
111.6%
7D
6.3%

Author's Valuation

US$61.3

4.5% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 5.06%

Shared on24 Apr 25
Fair value Decreased 0.85%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 0.24%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 4.33%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 5.20%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.